Literature DB >> 23908482

Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.

Paolo Campoli1, David S Perlin, Arnold S Kristof, Theodore C White, Scott G Filler, Donald C Sheppard.   

Abstract

BACKGROUND: The antifungal posaconazole concentrates within host cells and protects against Aspergillus fumigatus. The specific subcellular location of posaconazole and the mechanism by which cell-associated posaconazole inhibits fungal growth remain uncharacterized.
METHODS: Posaconazole was conjugated with the fluorophore boron-dipyrromethene (BDP-PCZ). A549 pulmonary epithelial cells and A. fumigatus were exposed to BDP-PCZ individually and in coculture. BDP-PCZ subcellular localization and trafficking were observed using confocal microscopy and flow cytometry.
RESULTS: BDP-PCZ concentrated within A549 cell membranes, and in particular within the endoplasmic reticulum. Epithelial cell-associated BDP-PCZ rapidly transferred to and concentrated within A. fumigatus cell membranes on contact. BDP-PCZ transfer to conidia did not require phagocytosis and was markedly enhanced by the conidial hydrophobin RodA. Within AF, BDP-PCZ also concentrated in membranes including the endoplasmic reticulum and colocalized with the azole target enzyme CYP51a. Concentration of BDP-PCZ within host and fungal cell membranes persisted for >48 hours and could be competitively inhibited by posaconazole but not voriconazole.
CONCLUSIONS: Posaconazole concentrates within host cell membranes and rapidly transfers to A. fumigatus, where it accumulates to high concentrations and persists at the site of its target enzyme. These intracellular and intercellular pharmacokinetic properties probably contribute to the efficacy of PCZ.

Entities:  

Keywords:  Aspergillus; endoplasmic reticulum; epithelial cells; hydrophobin rodA; localization; pharmacokinetics; posaconazole; postantifungal effect

Mesh:

Substances:

Year:  2013        PMID: 23908482      PMCID: PMC3805237          DOI: 10.1093/infdis/jit358

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity.

Authors:  Leila M Lopes Bezerra; Scott G Filler
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

2.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

5.  Evaluation of fungal-specific fluorescent labeled echinocandin probes as diagnostic adjuncts.

Authors:  Ayiasha Pratt; Guillermo Garcia-Effron; Yanan Zhao; Steven Park; Arkady Mustaev; Shyamala Pillai; David S Perlin
Journal:  Med Mycol       Date:  2012-05-15       Impact factor: 4.076

6.  Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Authors:  Hanan K Munayyer; Paul A Mann; Andrew S Chau; Taisa Yarosh-Tomaine; Jonathan R Greene; Roberta S Hare; Larry Heimark; Robert E Palermo; David Loebenberg; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.

Authors:  Andrew J Ullmann; Erik Krammes; Sita Sommer; Ines Buschmann; Bernhard Jahn-Muehl; Anthony Cacciapuoti; Heinz-Josef Schmitt
Journal:  J Antimicrob Chemother       Date:  2007-09-12       Impact factor: 5.790

8.  rodletless mutants of Aspergillus fumigatus.

Authors:  N Thau; M Monod; B Crestani; C Rolland; G Tronchin; J P Latgé; S Paris
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

9.  Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

Authors:  Li Xiao; Vincent Madison; Andrew S Chau; David Loebenberg; Robert E Palermo; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Transcriptional profiling identifies a role for BrlA in the response to nitrogen depletion and for StuA in the regulation of secondary metabolite clusters in Aspergillus fumigatus.

Authors:  Kwame Twumasi-Boateng; Yan Yu; Dan Chen; Fabrice N Gravelat; William C Nierman; Donald C Sheppard
Journal:  Eukaryot Cell       Date:  2008-11-21
View more
  22 in total

1.  Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity.

Authors:  Brendan D Snarr; Perrin Baker; Natalie C Bamford; Yukiko Sato; Hong Liu; Mélanie Lehoux; Fabrice N Gravelat; Hanna Ostapska; Shane R Baistrocchi; Robert P Cerone; Elan E Filler; Matthew R Parsek; Scott G Filler; P Lynne Howell; Donald C Sheppard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-20       Impact factor: 11.205

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 3.  Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors:  Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal:  Med Mycol       Date:  2019-04-01       Impact factor: 4.076

4.  Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story.

Authors:  Donald C Sheppard; Paolo Campoli; Rafael F Duarte
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

5.  Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.

Authors:  Jürgen Prattes; Wiebke Duettmann; Martin Hoenigl
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 6.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

7.  Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.

Authors:  Shane R Baistrocchi; Mark J Lee; Melanie Lehoux; Benjamin Ralph; Brendan D Snarr; Robert Robitaille; Donald C Sheppard
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

8.  Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function.

Authors:  Emily E Rosowski; Jiaye He; Jan Huisken; Nancy P Keller; Anna Huttenlocher
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

9.  Overlapping and distinct roles of Aspergillus fumigatus UDP-glucose 4-epimerases in galactose metabolism and the synthesis of galactose-containing cell wall polysaccharides.

Authors:  Mark J Lee; Fabrice N Gravelat; Robert P Cerone; Stefanie D Baptista; Paolo V Campoli; Se-In Choe; Ilia Kravtsov; Evgeny Vinogradov; Carole Creuzenet; Hong Liu; Albert M Berghuis; Jean-Paul Latgé; Scott G Filler; Thierry Fontaine; Donald C Sheppard
Journal:  J Biol Chem       Date:  2013-11-20       Impact factor: 5.157

Review 10.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.